A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension

Compliance Study Comparing DuoTrav to TRAVATAN Plus Timolol Using the Dosing Aid

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00465803

Enrollment

Registered

2007-04-25

Start date

2007-03-31

Completion date

Unknown

Last updated

2014-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open-angle Glaucoma, Ocular Hypertension

Keywords

Open-angle glaucoma or ocular hypertension

Brief summary

The purpose of this study is to assess patient compliance with DuoTrav versus concomitant administration of Timolol 0.5% plus TRAVATAN in patients with open-angle glaucoma or ocular hypertension.

Interventions

DRUGTravoprost 0.004%/timolol 0.5% ophthalmic solution

One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months using the Dosing Aid

DRUGTravoprost ophthalmic solution, 0.004%

One drop in the study eye(s) once daily at 8 PM for twelve months using the Dosing Aid

DRUGTimolol maleate ophthalmic solution, 0.5%

One drop in the study eye(s) once daily at 8 AM or twelve months using the Dosing Aid

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients with open-angle glaucoma or ocular hypertension; * Other protocol-defined inclusion criteria may apply.

Exclusion criteria

* Visual acuity worse than 0.60; * Other protocol-defined

Design outcomes

Primary

Measure	Time frame	Description
Patient compliance	12 months	Patient compliance will be measured with a dosing aid that records time and date of study drug administration

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026